Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Genitourinary Cancers
Are there studies looking at Ra-223 and SBRT for oligometastatic disease in the setting of mCRPC?
Answer from: Radiation Oncologist at Community Practice
Yes, quite a few including one from UCLA- NCT05496959
Sign in or Register to read more
18046
Related Questions
Would you give immunotherapy after neoadjuvant gem-cis for bladder cancer if cystectomy is being postponed for months due to non-autoimmune/unrelated comorbidities?
When treating an inoperable urothelial cancer of the renal pelvis, what are your considerations when determining candidacy for SBRT?
How do you reconcile discordant PSMA and MRI findings in patients undergoing definitive radiotherapy for prostate cancer?
Why is there a benefit of ADT for high risk prostate cancer treated with radiation, yet no large trials describing benefit of adjuvant ADT after radical prostatectomy?
Given the PATRIOT trial and hypo-FLAME 2.0, do you consider once-a-week prostate SBRT instead of every other day?
How would you manage an aortocaval nodal recurrence of prostate cancer in a patient who previously received salvage radiation to the fossa and pelvic nodes?
How do you decide between internal versus external decompression of malignant obstruction of the ureter (MUO)?
How do you follow/manage patients with metastatic prostate cancer with undetectable PSA and castration-sensitive but active disease on PSMA PET?
What adjuvant treatment would you offer a patient who underwent cystoprostatectomy for a muscle invasive bladder cancer and discovered to also have prostate cancer?
For a patient post-prostatectomy with a high PSA (>1), a negative MRI pelvis, and a negative PSMA PET scan, do you pursue any other imaging?